Article
Predictors of consent to pharmacogenomics testing in the IDEAL study.
Pharmacogenetics and genomics - 1 Nov 2013
Jazwinski Alison B, Clark Paul J, Thompson Alexander J, Gordon Stuart C, Lawitz Eric J, Noviello Stephanie, Brass Clifford A, Pedicone Lisa D, Albrecht Janice K, Sulkowski Mark S, Muir Andrew J
Abstract excerpt
INTRODUCTION: Pharmacogenomic testing is important in developing individualized therapeutic approaches. In the phase 3 IDEAL (Individualized Dosing to Assess Optimal Pegylated Interferon Therapy) clinical trial, a subset of patients receiving peginterferon and ribavirin for treatment of chronic hepatitis C agreed to provide blood samples for genetic testing. Genome-wide association studies subsequently identified...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.